Maxcyte (MXCT) Payables (2020 - 2026)

Maxcyte (MXCT) has 7 years of Payables data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Payables fell 47.52% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 47.52% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, up 3.17% from the prior year.
• Payables for Q1 2026 stood at $1.2 million, down from $1.4 million in the prior quarter.
• Over the last five years, Payables for MXCT reached as high as $4.4 million in Q1 2022 and fell as low as $292000.0 in Q4 2022.
• Historically, Payables has averaged $1.7 million across 5 years, with a median of $1.4 million in 2025.
• Across the five-year window, Payables slumped 83.96% in 2022 and jumped 317.6% in 2024, its largest moves.
• Year by year, Payables stood at $292000.0 in 2022, then soared by 154.45% to $743000.0 in 2023, then soared by 82.77% to $1.4 million in 2024, then increased by 3.17% to $1.4 million in 2025, then declined by 14.63% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $1.2 million in Q1 2026, $1.4 million in Q4 2025, and $1.3 million in Q3 2025.